Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 3/20 | 0.54 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.52 |
| ▸ | CTSL | P07711 | 2/20 | 0.49 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.46 |
| ▸ | KLK7 | P49862 | 1/20 | 0.46 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31725820 | 0.89 | TACR1 (0.61) | TACR1SCN9ACTSLCTSSCTSK | |
| SCHEMBL6853261 | 0.86 | HDAC3 (0.48) | TACR1SCN9ACTSLCTSSCTSK | |
| SCHEMBL6853259 | 0.86 | HDAC3 (0.48) | TACR1SCN9ACTSLCTSSCTSK | |
| SCHEMBL17961906 | 0.85 | TACR1 (0.59) | TACR1SCN9ACTSLCTSSCTSK | |
| SCHEMBL17961907 | 0.85 | TACR1 (0.59) | TACR1SCN9ACTSLCTSSCTSK | |
| SCHEMBL5123229 | 0.84 | TACR1 (0.62) | TACR1SCN9ACTSLCTSSCTSK | |
| SCHEMBL14032553 | 0.84 | TACR1 (0.64) | TACR1SCN9ACTSLCTSSCTSK | |
| SCHEMBL5123222 | 0.84 | TACR1 (0.62) | TACR1SCN9ACTSLCTSSCTSK | |
| SCHEMBL21310053 | 0.84 | TACR1 (0.62) | TACR1SCN9ACTSLCTSSCTSK | |
| SCHEMBL21310052 | 0.83 | TACR1 (0.53) | TACR1SCN9ACTSLCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6831175-B2 | Such as N,N-dimethyl-N-(2-((5-((E)-2-pyridin-4-ylvinyl) pyridin-3-yl)oxy)ethyl)amine | ABBOTT LABORATORIES | 2004-12-14 | — | — | US | disclosed |
| US-20030199511-A1 | Kinase inhibitors | ABBVIE INC. | 2003-10-23 | — | — | US | disclosed |
| US-20030187026-A1 | Kinase inhibitors | ABBOTT LABORATORIES | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187026-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | TACR1 4676/4885SCN9A 2367/4885CTSL 3589/4885 |
| US-20030199511-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | TACR1 4676/4885SCN9A 2367/4885CTSL 3589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.